$EVAX News

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026

Reported Sunday, Evaxion Presents New Preclinical Data Showing Multi-Component EVX-V1 Vaccine Pairs AI-Discovered Antigens With AI-Optimized Antigens To Target CMV From Multiple Angles

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop

Evaxion To Present New Preclinical Data For Vaccine Candidate EVX-V1 In Poster Session At IHW 2026

Evaxion receives Prix Galien UK Award for Best digital health solution

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion Says AI-Immunology-Developed EVX-04 Shows Immune Activation And Targeted Cell-Killing In Preclinical Acute Myeloid Leukemia Data

Evaxion A/S 2026 Q1 - Results - Earnings Call Presentation

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Evaxion To Present Preclinical EVX-04 AML Vaccine Data At EHA 2026, Advancing Toward Planned Clinical Trial Submission In 2H 2026

European Equities Traded in the US as American Depositary Receipts Rise Friday

Evaxion (EVAX) Q1 2026 Earnings Transcript

Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript

Evaxion (NASDAQ:EVAX) Beats on Operating Metrics, but Market Waits for Revenue

Evaxion announces business update and first quarter 2026 financial results

Evaxion Biotech Q1 EPS $(0.01) Beats $(0.23) Estimate

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer